// App-Quantinova.ai

: Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial

Researchers

Presenter

  • Kevin R. Flaherty

Principal Investigators

  • Athol U. Wells

  • Vincent Cottin

  • Anand Devaraj

  • Yoshikazu Inoue

  • Luca Richeldi

  • Simon L. F. Walsh

  • Martin Kolb

  • Dirk Koschel

  • Teng Moua

  • Susanne Stowasser

  • Rainer-Georg Goeldner

  • Rozsa Schlenker-Herceg

  • Kevin K. Brown

Medical Centers

  • Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, United States of America

  • National Institute for Health Research, Cardiovascular Research Unit, Royal Brompton and Harefield NHS Trust, London, United Kingdom

  • National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France,

  • Department of Radiology, Royal Brompton and Harefield NHS Foundation Trust, London, UK and National Heart and Lung Institute, Imperial College, London, United Kingdom

  • Clinical Research Cente, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan,

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy

  • National Heart and Lung Institute, Imperial College London, London, United Kingdom

  • McMaster University and St. Joseph’s Healthcare, Hamilton, Ontario, Canada

  • Fachkrankenhaus Coswig, Coswig, Germany

  • Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, United States of America

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany

  • Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States.

  • Department of Medicine, National Jewish Health, Denver, CO, United States,

Locations

  • United States

  • United Kingdom

  • France

  • Japan

  • Italy

  • Canada

  • Germany

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved